These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 22914623)

  • 21. Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.
    Zhang H; Liu C; Chen Q; Shen LA; Xiao W; Li J; Wang Y; Zhu D; Zhang Q; Li J
    J Med Chem; 2023 Jan; 66(2):1349-1379. PubMed ID: 36630177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
    El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
    Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.
    Moor AE; Anderle P; Cantù C; Rodriguez P; Wiedemann N; Baruthio F; Deka J; André S; Valenta T; Moor MB; Győrffy B; Barras D; Delorenzi M; Basler K; Aguet M
    EBioMedicine; 2015 Dec; 2(12):1932-43. PubMed ID: 26844272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells.
    Sinner D; Kordich JJ; Spence JR; Opoka R; Rankin S; Lin SC; Jonatan D; Zorn AM; Wells JM
    Mol Cell Biol; 2007 Nov; 27(22):7802-15. PubMed ID: 17875931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling.
    Hoffmans R; Basler K
    Mech Dev; 2007 Jan; 124(1):59-67. PubMed ID: 17113272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
    Mani M; Carrasco DE; Zhang Y; Takada K; Gatt ME; Dutta-Simmons J; Ikeda H; Diaz-Griffero F; Pena-Cruz V; Bertagnolli M; Myeroff LL; Markowitz SD; Anderson KC; Carrasco DR
    Cancer Res; 2009 Oct; 69(19):7577-86. PubMed ID: 19738061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Wang Z; Zhang M; Luo W; Zhang Y; Ji H
    J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decoding the dynamics of BCL9 triazole stapled peptide.
    Gaikwad V; Choudhury AR; Chakrabarti R
    Biophys Chem; 2024 Apr; 307():107197. PubMed ID: 38335808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin.
    Lo YH; Noah TK; Chen MS; Zou W; Borras E; Vilar E; Shroyer NF
    Gastroenterology; 2017 Jul; 153(1):205-218.e8. PubMed ID: 28390865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
    de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
    Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
    Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
    Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
    Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
    Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
    Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
    J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C644-0303, a small-molecule inhibitor of the Wnt/β-catenin pathway, suppresses colorectal cancer growth.
    Yan Y; Zhang Y; Li M; Zhang Y; Zhang X; Zhang X; Xu Y; Wei W; Wang J; Xu X; Song Q; Zhao C
    Cancer Sci; 2021 Nov; 112(11):4722-4735. PubMed ID: 34431598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Wang Z; Zhang M; Quereda V; Frydman SM; Ming Q; Luca VC; Duckett DR; Ji H
    J Med Chem; 2021 Aug; 64(16):12109-12131. PubMed ID: 34382808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aristaless Related Homeobox (ARX) Interacts with β-Catenin, BCL9, and P300 to Regulate Canonical Wnt Signaling.
    Cho IT; Lim Y; Golden JA; Cho G
    PLoS One; 2017; 12(1):e0170282. PubMed ID: 28103279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure analysis of the PHD domain of the transcription co-activator Pygopus.
    Nakamura Y; Umehara T; Hamana H; Hayashizaki Y; Inoue M; Kigawa T; Shirouzu M; Terada T; Tanaka A; Padmanabhan B; Yokoyama S
    J Mol Biol; 2007 Jun; 370(1):80-92. PubMed ID: 17499269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins.
    Jiang M; Kang Y; Sewastianik T; Wang J; Tanton H; Alder K; Dennis P; Xin Y; Wang Z; Liu R; Zhang M; Huang Y; Loda M; Srivastava A; Chen R; Liu M; Carrasco RD
    Nat Commun; 2020 Jan; 11(1):19. PubMed ID: 31911584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.
    Zhao JJ; Lin J; Zhu D; Wang X; Brooks D; Chen M; Chu ZB; Takada K; Ciccarelli B; Admin S; Tao J; Tai YT; Treon S; Pinkus G; Kuo WP; Hideshima T; Bouxsein M; Munshi N; Anderson K; Carrasco R
    Cancer Res; 2014 Mar; 74(6):1801-13. PubMed ID: 24599134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CREPT/RPRD1B, a recently identified novel protein highly expressed in tumors, enhances the β-catenin·TCF4 transcriptional activity in response to Wnt signaling.
    Zhang Y; Liu C; Duan X; Ren F; Li S; Jin Z; Wang Y; Feng Y; Liu Z; Chang Z
    J Biol Chem; 2014 Aug; 289(33):22589-22599. PubMed ID: 24982424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.